Cardiogen: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 9 sources cited

Overview

Cardiogen is a Khavinson bioregulator tetrapeptide (Ala-Glu-Asp-Arg) aimed at cardiac muscle tissue. In rat experiments it reduced heart damage and deaths after an induced heart attack, and in tissue culture it stimulated growth of heart cells; it has not been tested in a published human study. Developed at the St. Petersburg Institute of Bioregulation and Gerontology, it belongs to a family of peptides this group has studied since the 1970s, but the published human studies concern other preparations such as Thymalin and Epithalamin, not Cardiogen.

Mechanism of Action

Cardiogen is proposed to interact with chromatin and change gene transcription; the tetrapeptide Ala-Glu-Asp-Arg binds histones in test-tube experiments. In cultured mouse embryonic fibroblasts it raised expression of cytoskeletal proteins (actin, tubulin, vimentin) 2–5 times and nuclear matrix proteins (lamin A, lamin C) 2–3 times. In myocardial tissue culture from young and old rats it stimulated cell proliferation and lowered the pro-apoptotic protein p53, and in animal models of heart injury it reduced lipid peroxidation. Effects on myosin, titin, calcium handling proteins or Bcl-2 have not been published. This modulation is proposed to help restore cardiac gene expression patterns that decline with aging. Improved contractile efficiency and calcium cycling have not been demonstrated; the resistance to ischemic stress was seen in rat experiments.

Cardiogen Benefits: What the Research Shows

  • Khavinson Institute tissue-culture studies showed that Cardiogen stimulated cell proliferation and lowered p53 expression in myocardial explants from young and old rats. No published study of cardiac function (ejection fraction, fractional shortening) in patients was found.
  • Preclinical models showed cardioprotective effects: after coronary artery ligation in rats, the peptide cut post-infarction mortality about threefold and reduced necrotic zones, and in other animal experiments it lessened calcium chloride-induced arrhythmia.
  • No published clinical study of Cardiogen in elderly cardiovascular patients was found; the long-term human data from this group concern Thymalin and Epithalamin.
  • Short bioregulatory peptides, including the Cardiogen sequence, have been shown to bind histones and DNA in test-tube fluorescence experiments and in molecular modeling, which supports but does not confirm the proposed epigenetic mechanism.

Cardiogen Dosage

  • Standard dose: 10 mg subcutaneous injection daily.
  • Typical cycle: 10–20 days, matching the standard bioregulator protocol.
  • Repeat every 3–6 months for maintenance cardiovascular support.
  • Often combined with Vesugen (vascular bioregulator) for comprehensive cardiovascular support — Cardiogen for the heart muscle, Vesugen for the blood vessels.
  • Can be incorporated into seasonal bioregulator anti-aging protocols alongside other tissue-specific bioregulators.
  • No specific food timing requirements. Inject subcutaneously in the abdomen or thigh.
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Cardiogen Side Effects & Safety

Known Side Effects

  • Injection site reactions — mild and uncommon, consistent with other bioregulator peptides.
  • No published human study has reported on adverse events with Cardiogen; the available studies are in cell culture and rats.
  • Cardiovascular adverse events (arrhythmia, blood pressure changes) have not been assessed in a published human study of Cardiogen.
  • The short treatment cycle (10–20 days) inherently limits exposure and risk.
  • Hormonal and metabolic effects have not been studied in humans.

Safety Profile

Cardiogen has no published human safety study, including in elderly patients with existing cardiovascular disease; the evidence is cell-culture and rat work from the group that developed it and its collaborators. As a short peptide it is expected to be rapidly metabolized and weakly immunogenic, but this has not been measured. Its acute effects on heart rate, blood pressure, or cardiac rhythm in people have not been studied. Contraindications are minimal: known hypersensitivity and pregnancy/breastfeeding. Interactions with cardiovascular medications (anticoagulants, antihypertensives, statins, beta-blockers) have not been studied, so its safety alongside standard cardiac care is unknown. Patients with acute myocardial conditions should be stabilized before beginning a bioregulator protocol.

What to Expect

Days 1–10: No immediate subjective cardiac effects. The bioregulator is interacting with cardiac gene regulatory regions, modulating expression patterns. This is a sub-perceptible molecular process. Days 11–20: The epigenetic reset is establishing. Some users report subtle improvements in exercise tolerance or reduced perception of cardiac effort, though these are difficult to attribute definitively to the bioregulator. Weeks 3–12 (post-cycle): Suppliers and users say benefits manifest and persist after the treatment course. No published study has measured cardiac function on echocardiography after Cardiogen, and reports of enhanced exercise tolerance and cardiac recovery are anecdotal. Months 3–6: Effects from the cycle gradually wane, signaling the appropriate time for a repeat course. The maintenance schedule of every 3–6 months sustains the epigenetic benefits long-term.

Common Stacks

Storage & Handling

Store lyophilized powder refrigerated at 36–46°F (2–8°C). After reconstitution, refrigerate and use within 20 days. Unreconstituted powder shelf life: 24 months. Oral capsules: store at room temperature in a cool, dry place.

Pricing & Available Variants

$50price range
20mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Khavinson V, Linkova N, Dyatlova A, et al. Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation. Cells. 2022.
  2. Ryzhak GA, Popovich IG, Kozina LS, et al. Peptidergic regulation of age-related alterations in the cardiovascular system. Adv Gerontol. 2026.
  3. Khavinson VKh, Lin'kova NS, Polyakova VO, et al. Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins. Bull Exp Biol Med. 2012.
  4. Chalisova NI, Lesniak VV, Balykina NA, et al. The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats. Adv Gerontol. 2009.
  5. Zakutskiĭ AN, Chalisova NI, Ryzhak GA, et al. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. Adv Gerontol. 2006.
  6. Fedoreyeva LI, Smirnova TA, Kolomijtseva GY, et al. Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides. Biochemistry (Mosc). 2013.
  7. Khavinson VK, Popovich IG, Linkova NS, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021.
  8. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results. Adv Gerontol. 2013.
  9. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003.

Related Peptides

Track Cardiogen in Your Protocol

Log your Cardiogen doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free